Avastin Plus Chemo Equals Higher Death Risk: Study

Law360, New York (February 2, 2011, 1:28 PM EST) -- In another blow to Genentech Inc.'s blockbuster cancer drug Avastin, a new analysis suggests the medication's use in combination with chemotherapy or biological therapy is linked to a higher risk of treatment-related death than chemotherapy alone.

The analysis of previous studies, published in Wednesday's issue of the Journal of the American Medical Association, comes less than two months after the U.S. Food and Drug Administration announced it would begin the process of pulling its approval of Avastin for use in breast cancer patients.

The analysis —...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.